The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans

Abstract

The partial agonist buspirone has a REM (rapid eye movement) suppressing effect on human sleep probably via a 5HT_1A receptor in the pontine area. Eptapirone is a new 5HT_1A agonist with a greater intrinsic effect than buspirone. The objective of this study was to examine the effects of eptapirone on sleep architecture, particularly REM sleep, in normal volunteers and compare it with buspirone and placebo. This was a randomized, double-blind placebo-controlled four-way crossover study in 12 healthy volunteers. Volunteers were screened to ensure that they had normal overnight sleep EEG (electroencephalogram) and were extensive CYP 2D6 metabolizers. Sleep was recorded on pairs of nights on four occasions, with medication being taken before the second night. Treatments were eptapirone 1.5mg at 10 AM, eptapirone 1.5mg at 11 PM, buspirone 20mg at 11 PM and placebo. Standard measures of sleep were derived and compared among the four treatments using ANOVA. REM sleep was significantly suppressed supporting the proposition that activation of post-synaptic 5HT_1A receptors reduces REM sleep. Sleep fragmentation increased by both drugs. REM sleep suppression was significantly greater with morning eptapirone than with buspirone. Wakefulness in sleep was significantly greatest after morning eptapirone. REM sleep effects were greatest after evening eptapirone, suggesting a greater effect on central serotonin receptors than that of buspirone.

Keywords

sleep REM sleep serotonin 5HT1A receptor 5HT1A agonist

Get full access to this article

View all access options for this article.

References

Ansseau M , Pitchot W , Gonalez-Moreno A (1992) Flesinoxan, a 5HT1Aagonist, in major depression: clinical efficacy and effects on REM latency and body temperature (open study). European Neuropsychopharmacology 2: 313

de Bruyn S , Tournoux A , Deprez D , Pezous N , Lafon M (2002). Study of the tolerability, pharmacodynamics and pharmacokinetics of F 11440 administered in repeated doses for 14 days. Pierre Fabre internal report No L0068 GE 101

Driver H S , Flanigan M J , Bentley A J , Luus H G , Shapiro C M , Mitchell D (1995) The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects. Psychopharmacology (Berl) 117(2): 186-192

Gillin J C , Jernajczyk W , Valladares-Neto D C , Golshan S , Lardon M , Stahl S M (1994) Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacology (Berl) 116(4): 433-436

Gillin J C , Sohn J W , Stahl S M , Lardon M , Kelsoe J , Rapaport M , Ruiz C , Golshan S. (1996) Ipsapirone, a 5-HT1A agonist, suppresses REM sleep equally in unmedicated depressed patients and normal controls. Neuropsychopharmacology 15(2): 109-115

Koek W , Patoiseau J F , Assie M B , Cosi C , Kleven M S , Dupont-Passelaigue E , Carilla-Durand E , Palmier C , Valentin J P , John G , Pauwels P J , Tarayre J P , Colpaert F C (1998) F11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. Journal of Pharmacology and Experimental Therapeutics 287: 266-283

Manfredi R L , Kales A , Vgontzas A N , Bixler E O , Isaac M A , Falcone C M (1991) Buspirone: sedative or stimulant effect? Am J Psychiatry 148(9): 1213-1217

Monaca C , Boutrel B , Hen R , Hamon M , Adrien J (2003) 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 28(5): 850-856

Monti J M , Monti D (2000) Role of dorsal raphe nucleus serotonin 5HT1a receptor in the regulation of REM sleep. Life Sciences 66: 1999-2012.

10.

Moore P , Gillin C , Bhatti T , DeModena A , Seifritz E , Clark C , Stahl S , Rapaport M , Kelsoe J (1998) Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry 55(6): 534-539

11.

Moore P , Seifritz E , Schlosser A , Greenfield D , Stahl S , Rapaport M , Kelsoe J (2001) Rapid tryptophan depletion plus a serotonin 1A agonist: competing effects on sleep in healthy men. Neuropsychopharmacology 25(5 Suppl): 540-544

12.

Parrot A C , Hindmarch I (1978) A factor analysis of a sleep evaluation questionnaire. Psychological Medicine 8: 325-329

13.

Seifritz E , Moore P , Trachsel L , Bhatti T , Stahl S M , Gillin J C (1996) The 5-HT1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockade. Neurosci Lett 209(1): 41-44

14.

Ware J C , Rose F V , McBrayer R H (1994) The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 17(6): 544-550

15.

Wilson S J , Argyropoulos S V (2005) Antidepressants and sleep. Drugs 65 (7): 927-947

16.

Wilson S J , Bailey J E , Nutt D J (2005) Dizziness produced by a potent 5HT(1A) receptor agonist (eptapirone) is not due to postural hypotension. Psychopharmacology (Berl) 179(4): 895-896

17.

Yocca F D (1990) Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors. J Clin Psychopharmacol 10(3 Suppl): 6S-12S